What is the current stock price of Galera Therapeutics, Inc. (GRTX)?

As of the latest market data, Galera Therapeutics, Inc. (GRTX) is trading at $0.04. The stock has seen a gain of 2.44% today.

Does Galera Therapeutics, Inc. (GRTX) pay a dividend?

Based on current data, Galera Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Galera Therapeutics, Inc.?

The current market capitalization of Galera Therapeutics, Inc. (GRTX) is approximately unavailable.

GRTX

Galera Therapeutics, Inc.·Healthcare

0.04

2.439%(+0.00)

Close Price

0.05

7.143%(+0.00)

Pre-Market

Last Updated: — ET

52W L: $0.0152W H: $0.06

GRTX NEWS

businesswire.com

4h ago

Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

CAMBRIDGE, Mass. & MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer, and Obsidian Therapeutics, Inc. (“Obsidian”), a privately-held clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocyte, (“TIL”), c.

defenseworld.net

Feb 16

Athersys (NASDAQ:ATHX) and Galera Therapeutics (NASDAQ:GRTX) Critical Review

Risk and Volatility Galera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Valuation and Earnings This table compares Galera Therapeutics and Athersys"s gross revenue,

Company Profile

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-11-07

Beta

1.77

Websitewww.galeratx.com↗